Korro Bio, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Korro Bio, Inc. (KRRO) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes genetic medicines utilizing its proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform to deliver precise, transient single-base RNA edits for rare and prevalent diseases targeting the liver and central nervous system. The company offers RNA editing oligonucleotides including its lead candidate KRRO-110, an intravenously delivered lipid nanoparticle-formulated therapy in Phase 1/2 clinical trials repairing the SERPINA1 Z mutation to restore normal alpha-1 antitrypsin (AAT) protein levels for alpha-1 antitrypsin deficiency (AATD) affecting liver and lung; KRRO-121, a GalNAc-conjugated oligonucleotide in preclinical development generating a stabilized enzyme variant for urea cycle disorders and hepatic encephalopathy; a subcutaneous GalNAc program in preclinical development also targeting the SERPINA1 gene for AATD; proprietary oligonucleotides in discovery/preclinical stages targeting TAR DNA-binding protein 43 (TDP-43) mRNA to disrupt aggregation in amyotrophic lateral sclerosis (ALS); and oligonucleotides selectively modulating NaV1.7 ion channels for subsets of chronic pain as non-opioid therapeutics. Korro Bio, founded in 2018, maintains headquarters in Cambridge, Massachusetts, and operates primarily in the United States with a focus on genetically validated targets in patient populations underserved by existing therapies. Recent developments include a September 2024 collaboration with Novo Nordisk A/S providing up to $530 million in upfront, milestone and royalty payments for two preclinical cardiometabolic programs advanced by Korro prior to potential handover, placed on 12-month hold in November 2025 alongside a 34% workforce reduction and chief medical officer resignation; a 2024 all-stock merger with Frequency Therapeutics enabling Nasdaq listing under KRRO; and a $116 million Series B financing to support pipeline advancement.
Company News
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of “Moderate Buy” by Brokerages
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro to Participate in Upcoming Investor Conferences
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Moderate Buy” by Analysts
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Reviewing Korro Bio (NASDAQ:KRRO) and Enlivex Therapeutics (NASDAQ:ENLV)
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Korro to Present at the 2026 Jefferies Global Healthcare Conference
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro to Participate in Upcoming Investor Conferences
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Recommendation of “Moderate Buy” from Analysts